NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy

Clinical trial registration, sponsored by M.D. Anderson Cancer Center, registered 13 Nov 2025.

Phase 2 · suspended · n = 90

Tags: Registry, Psilocybin, Pain, Cancer.

Weekly Science Digest, 13 Nov 2026 to 19 Nov 2026, finding 6: In the clinic

suspended at PI request: MD Anderson's trial of psilocybin to prevent chemotherapy-induced peripheral neuropathy

How much weight it carries: Trial registry movements: what is being attempted, not what was found. (Registry, Plans, not results)

Weekly Science Digest, 20 Jul 2026 to 2 Oct 2026, finding 1: Psilocybin prevented chemotherapy nerve damage in mice

Two doses of psilocybin before platinum or taxane chemotherapy stopped peripheral neuropathy from developing, across repeated chemo cycles, without weakening the chemotherapy against tumors. The authors trace the effect to nerve cells keeping their mitochondria moving along the axon.

How much weight it carries: Animal study. A human trial testing psilocybin to prevent chemo-induced neuropathy is registered at MD Anderson. (Mice, Preclinical, Peer reviewed)

Read the original

—
Node—
Statuslive
Throughput—